Samsung Partners with Alcedis to Use Wearable Data in Clinical Trials
Samsung Partners with Alcedis to Use Wearable Data in Clinical Trials
Updated at: June 24, 2026 at 04:45 AM
On June 24, 2026, Samsung Electronics announced a strategic partnership with Alcedis, a German clinical research organization, to transform how clinical trials are conducted.
The collaboration focuses on integrating biometric data from the Samsung Galaxy Watch into drug development processes.
By turning raw physiological data—such as heart rate, sleep patterns, and activity levels—into standardized clinical evidence, this initiative supports more flexible, decentralized clinical trials (DCTs).
This approach moves research away from hospital-only settings, reducing the burden on patients while enabling continuous health monitoring in their daily lives.
Alcedis, a subsidiary of the Huma Group, leverages its decades of expertise in oncology and cardiology to ensure that Samsung’s hardware translates effectively into regulated clinical outcomes.
This partnership bridges the gap between consumer wearables and professional medical research, aiming to shorten development timelines and improve data reliability.
Ultimately, this synergy seeks to accelerate the delivery of new, life-changing therapies to patients worldwide, marking a pivotal step forward in the evolution of digital-first medical research.
